Peace of Mind through Redefined Cancer Survelliance
Matrix-Bio is employing metabolite profiling to create powerful
new cancer diagnostic tests that provide an instantaneous snapshot
of a patient's metabolism. These tests will detect the presence and
reoccurrence of cancer and monitor treatment with greater accuracy,
speed, and less discomfort to the patient than current testing
methodologies. We are redefining hope.
MetaMarker-BCR Breast Cancer Test
There are currently 2.5 million breast cancer survivors who may benefit from recurrence monitoring. This new recurrence-monitoring test measures key metabolic changes to quickly and accurately detect the return of cancer.
Investor Ready
Matrix-Bio expects to go to market with the world's first metabolite-based commercial test for breast cancer in mid-2011. We are currently in the process of raising series A equity.
News
Main Street Venture Funds Invests in Breast Cancer Recurrence Test
The Fort Wayne-based angel investment group is investing in Matrix-Bio, Inc., a Purdue Research Park company with new technology that shows great potential for early breast cancer detection and recurrence monitoring.
Your Questions Answered
What is metabolite profiling? How does it benefit breast cancer patients and their physicians?